A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
NCT07687914
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
HCC - Hepatocellular Carcinoma
Interventions
DRUG:
IMM2510, IMM27M
Sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.